Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine
Completed · Phase 1 · Has a placebo group
Conditions studied: Parainfluenza, Virus Diseases
In brief
Human Parainfluenza Virus Type 1 (HPIV1) is a leading cause of viral respiratory infections in children, the elderly, and those with compromised immune systems. HPIV1 is also the leading cause of viral croup in children under 6 years old. The purpose of this study is to determine the safety of and immune response to a HPIV1 vaccine, rHPIVI1 84/del170/942A, in 2 groups of adults and then in children who have been previously exposed to HPIV1. Once the safety of this vaccine has been established in these groups, an additional 2 groups of infants and children who have not been previously exposed to HPIV1 will be vaccinated. Naïve infants and children are the most vulnerable to naturally circulating HPIV1 and are the target population of this vaccine.
Key facts
- Study ID
- NCT00641017
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 87
- Starts
- 2008-03-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2013-02-25
Who can join
Age: 1 and older, up to 49. Sex: any. Healthy volunteers: accepted.
Where it is running
- Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.